2018 Round Table
Biodrugs
The need for regulations or specifications concerning the registration of biosimilars
Evaluate biosimilars already on the market and associate the social security throughout the process of evaluation and registration of biomedicines
Put in place an adequate structure for the control
- What tools are needed : Evaluation, Registration, Dossier
Audience
- Director General of Social Security, Djaouad Bourkaib & Dr. Mohamed Lamine Ghanem
- Ministry of Health
- President of the Algerian Association for Biotechnology & Clinical Research, Salah Sahraoui
- National Institute of Public Health, Lyes Rahal
- National Laboratory for Control of Pharmaceutical Products
- WHO with M. Nabil Menasria
- The industry with UNOP & stakeholders
- KOL
Attending Experts
Pr. Ruth Lopert
Michael Muenzenberg
Wilkeir Ribeiro Filho
Dr. Valderilio Azevedo
EDUMED
